Global Acute Myeloid Leukemia Market to Value Over US$ 1.5 Billion by End of 2026

  • 03 Jun 2019

The global acute myeloid leukaemia market is poised to value over US$ 1.5 billion by the end of 2026 and registering a CAGR of over 12% during the forecast period, 2019 to 2026 

Radiation exposure, carcinogenic environmental components, unhealthy lifestyle and genetic mutations are mainly responsible for acute myeloid leukaemia (AML). The emergence of alternative AML therapeutics like Tyrosine Kinase Inhibitors, monoclonal antibodies and multidrug-resistant modulators provides significant benefits such as improved chances of early detection of cancer cells, improved quality and safety, reduction in relapse percentage, long term survival rates and so on.
Some of the major factors impelling the growth of the global acute myeloid leukaemia market include:
•    High mortality rate owing to AML
•    Increasing relapse incidences 
•    The limited response of present medical solutions to treat AML
•    Adverse effects of traditional treatments like tissue damage and loss of appetite in patients 
•    A rise in the cancer-prone ageing population
•    Innovative drug development solutions using molecular biology
•    Propelling investments in pharmaceutical R&D by market players 
•    Research incentives and rapid approvals by government bodies
•    Availability of tests that can predict the compatibility of a particular patient with drug or combination of drugs in achieving positive results

Global Acute Myeloid Leukemia Market Competitive Scenario
The small and mid-sized pharmaceutical companies are exhibiting prominent presence with technologically innovative therapeutic techniques providing viable results. The overall market players pool is competitive with major players like Teva Pharmaceuticals, Novartis AG and Pfizer. New drug pipelines, extensive clinical trials and collaborations to proliferate geographic presence would remain major attention area to gain a competitive advantage in coming years.

Global Acute Myeloid Leukemia Market Restraints
+ Lack of standardised treatments
+ Mounting preference towards stem cell replacement as an alternative solution
+ Heavily dominated market with the generics
+ High cost of therapeutic treatment processes coupled with safety apprehensions

Global Acute Myeloid Leukemia Market by Drug Class
+ Tyrosine Kinase Inhibitors
+ Hedgehog Pathway Inhibitors
+ Topoisomerase 2 Inhibitors
+ Others
Tyrosine Kinase Inhibitors have undergone clinical evaluation for identification of recurring mutations in all phases of drug development, clinical trials (both single agents plus combination with chemotherapeutics) with promising anti-leukemic activity outcomes. The biomolecule induces the mobilization of the hematopoietic progenitors and stem cells in vivo which potentially aid the human biological system to kill cancer cells. Hence this drug class segment is estimated to dominate the global AML market over the next couple of years.

Global Acute Myeloid Leukemia Market by End User
+ Hospital
+ Clinic
+ Others

Global Acute Myeloid Leukemia Market by Region
+ North America
+ Latin America
+ Europe
+ Asia Pacific
+ Rest of the World
North America leads the global acute myeloid leukaemia market due to existing patient base and healthcare setups. Besides, it has unique research and development infrastructure supported by government funds, leading pharmaceutical enterprises and healthcare organizations. This lead is further followed by the Europe region which is a hub for medical breakthroughs and skilled healthcare professionals. The APAC region is estimated to grow at a consistent CAGR in the near future due to increased awareness about AML, better healthcare infrastructure, rising disposable income and investment in healthcare innovation.

Competitive Landscape:  
+ Tier 1 players- established companies in the market with a major    market share
+ Tier 2 players 
+ Emerging players which are growing rapidly 
+ New Entrants  

FutureWise Key Takeaways 
+ Growth prospects
+ SWOT analysis 
+ Key trends 
+ Key data-points affecting market growth 

Objectives of the Study: 
+ To provide with an exhaustive analysis on the Global Acute Myeloid Leukemia Market by Drug Class, by End User and by Region
+ To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
+ To evaluate and forecast micro-markets and the overall market 
+ To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
+ To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
+ Profiling of companies to evaluate their market shares, strategies, financials and core competencies  


Get unlimited analyst support and customise this study further to your requirements, contact